Fig. 3. Pharmacogenetics of the β-blocker bucindolol in chronic heart failure. Shown are Kaplan-Meyer curves showing survival stratified by treatment group and the β1Arg- or β1Gly389 polymorphism. Those with the β1Arg389 genotype receiving bucindolol had a 38% improvement in survival over placebo patients of the same genotype. Gly389 carriers on bucindolol showed no improvement. From Liggett SB et al. , Proc Natl Acad Sci USA 2006; 103:11288–93. Reprinted with permission from the National Academy of Sciences, USA.63
